🐻 LYB $1.5M Bearish/Hedge Put Block — Wall Street's Bear Case Bought in Size

Last updated: 2026-06-04

✅ RESOLVED — Next-Day OI Update (2026-06-04): The $55 put OI rose 307 → 3,204 (+2,897) — the long-put (bear/hedge) BTO opened as predicted. Read confirmed.

📅 June 3, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just crossed ≈$1.5 MILLION in put options on LyondellBasell, betting on (or hedging against) a fall back toward the $55 level — which is essentially where the majority of Wall Street analysts already think this stock belongs. The buyer paid $5.00 per contract for 3,000 Jan-15-2027 puts at the $55 strike, with LYB sitting at $67.30. That's ≈18% out-of-the-money and ≈7.5 months until expiry — enough time to span two earnings prints, two dividend declarations, and a full chemicals-cycle read-through. This trade is buying the Street's average price target as a floor, either as outright bearish conviction or as portfolio insurance on a stock that just bounced ≈60% off multi-year lows on a margin tailwind that could reverse.

---

📊 Company Overview

LyondellBasell Industries N.V. (NYSE: LYB) is one of the world's largest plastics, chemicals, and refining companies, headquartered in Houston with operations across the Americas, Europe, and Asia.

• Market Cap: ≈$21.5–22 billion (June 2026)
• Sector: Materials / Commodity Chemicals (SIC: Specialty and Diversified Chemicals)
• Core Businesses: Olefins & polyolefins (ethylene, propylene, polyethylene, polypropylene — the building blocks of packaging, bottles, automotive parts, and films), intermediates & derivatives (oxyfuels, propylene oxide, styrene), advanced polymer solutions, and a technology licensing business
• Refining is gone: LYB ceased operations at its Houston refinery in February 2025 — the old refining-margin thesis no longer applies
• Dividend yield: ≈4.1% at current prices — but this is after a ≈50% dividend cut in February 2026, down from a yield that briefly hit ≈11% in late 2025

LYB is a textbook commodity-chemicals cyclical. Earnings swing hard with the "spread" between resin prices and feedstock costs, global operating rates, and oil/natural-gas prices. Right now it's deep in one of the most prolonged chemicals down-cycles in decades — and while the stock has bounced ≈60% year-to-date, that bounce is built on a war-driven, exogenous margin tailwind, not a structural demand recovery.

Real talk: the average Wall Street analyst price target is in the low-to-mid $50s — below today's ≈$67 price. This put buyer is, in effect, buying the analyst base case.

---

💰 The Option Flow Breakdown

📊 The Tape (June 3, 2026 @ 13:53:31)

Flow-type tag: 🤝 BLOCK CROSS — this was a negotiated single-leg cross, not an aggressive lit sweep. A broker matched a buyer and a seller off the open book; there is a known counterparty on the other side. Read this as a deliberate, positioned trade — not panic, not an urgent sweep buying into an offer.

Order type (classifier): BTO Long Put — MED confidence. Volume of 3,000 contracts is nearly 10 times the prior open interest of 307 (Vol/OI ≈9.8). When volume vastly exceeds OI like this, the vast majority of the size must be new opens — there simply are not enough existing long or short contracts to account for 3,000 closes on a 307-OI strike. This is overwhelmingly a new bearish or hedge position.

---

⏳ OI Check — Come Back Tomorrow Morning

Today's tape strongly supports a new open. With Vol/OI ≈9.8 (volume nearly 10× prior OI), at least ≈2,693 of the 3,000 contracts had to be opening trades regardless of what the other 307 did. Expect tomorrow's OPRA OI snapshot (≈06:30 ET, June 4) to show the $55 Jan-2027 put OI rise from ≈307 toward ≈3,000-3,307, confirming this as a fresh open long-put position.

📋 Prediction: OI should print ≈3,000–3,307 tomorrow morning (rise of ≈2,693–3,000). An OI rise of that magnitude = confirmed new open (BTO Long Put). If OI rises only partially (say ≈700–1,500), it would imply a mix of new opens and partial closes of an existing short-put position. If OI barely moves or falls, the read inverts.

Important caveat: Even with high Vol/OI confidence, we cannot see from the tape whether this put is an outright bearish directional bet or a hedge against a long LYB stock position. Both use the same instrument; the tape looks identical. We present both interpretations honestly throughout this analysis.

---

🤓 What This Actually Means — Plain English

Let's decode this step by step.

What is a Long Put?

When you buy a put option, you're paying for the right to sell 100 shares of LYB at the strike price ($55) any time before expiration (January 15, 2027). You don't have to own the stock — the put just gives you the right to "put it to" someone at $55.

• If LYB falls below $55, your put becomes more and more valuable. At $45, your $55 put has $10 of intrinsic value per share — per contract that's $1,000, and you paid $500.
• If LYB stays above $55, the put expires worthless and you lose the $5.00 premium per contract.

The key numbers:

• 3,000 contracts × 100 shares × $5.00 = $1,500,000 total premium paid
• Breakeven at expiration: $55.00 − $5.00 = $50.00 (LYB needs to trade at $50 or below at expiry for the put buyer to be in profit)
• The $55 strike is ≈18.2% below today's $67.30 spot — this is a meaningful out-of-the-money position
• Maximum profit: If LYB goes to $0, each contract is worth $5,500 (minus the $500 paid) — theoretical max gain ≈$15M for 3,000 contracts
• Maximum loss: $1,500,000 (the full premium paid, if LYB is above $55 on January 15, 2027)

The two honest readings of this trade:

Reading 1 — Outright bearish bet: The buyer believes LYB's ≈60% YTD bounce is overdone, that the margin tailwind from Middle East supply disruptions is temporary, and that as the war resolves and the chemicals down-cycle grinds on, LYB drifts back toward where analysts think it belongs: the low-to-mid $50s. The $55 put is a leveraged way to profit from that re-rating.

Reading 2 — Hedge on a long stock/dividend position: LYB has long been owned for its dividend income. After the ≈50% dividend cut in February 2026, some institutional holders are sitting on a position they cannot (or do not want to) sell easily. Buying protective puts is a clean way to cap the downside below $55 while keeping the dividend income. In this case, the "put buyer" is actually a long stock holder buying insurance — not a bear at all. The tape looks identical either way.

The dividend-cut bear thesis in plain English:

LYB cut its quarterly dividend from $1.37 to $0.69 in February 2026 — a ≈50% haircut. The new yield is ≈4.1% at $67. If earnings stay under pressure and free cash flow stays thin, a second dividend cut or suspension could trigger forced selling from income-focused funds who own LYB specifically for the yield. A second cut would likely send the stock toward (or through) the $55 level — which is where multiple analysts already have their price targets. The put buyer is either betting on that scenario or protecting against it.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

LYB is one of 2026's surprising outperformers — up ≈60% from a late-2025 trough near ≈$42, far outpacing the S&P 500. But zoom out and the picture is more complicated: the stock traded above $90 as recently as April 2024 and hit an all-time high of ≈$122 in 2018. Today's ≈$67 is still ≈26% below the 2024 high — the 2026 bounce is recovery from a severe collapse, not a return to all-time highs. And as of late May 2026, LYB logged a 6-day losing streak of −8.1%, a sign the momentum may be fading.

---

🛡️ Gamma-Based Support & Resistance

Current Price: ≈$67.20 (per GEX snapshot)

The gamma map for LYB paints a clearly bearish near-term skew — put gamma (blue bars, downside protection from market makers) is dominant at the key levels below spot, while call gamma (orange, upside resistance) builds meaningfully above $65–$75.

🟠 Call Gamma Resistance (Orange Bars — Overhead Sellers):

• $65 — Near-term balanced/call-dominant level, 1.54B total GEX, net GEX +0.30B (call-leaning). Immediately below spot — this level has already been reclaimed. Any dip back toward $65 would bring MM selling support.
• $72.5 — Moderate resistance, 0.87B total GEX, net GEX +0.15B call-dominant. The first meaningful ceiling above today's price.
• $75 — Strong call resistance, 1.33B total GEX, net GEX +0.91B call-dominant. A significant overhead wall — MMs will hedge into rallies approaching here.
• $80 — Moderate resistance, 0.96B total GEX, net GEX +0.79B call-dominant.
• $85 — Additional call wall, 0.48B total GEX, net GEX +0.46B.

🔵 Put Gamma Support (Blue Bars — Downside Floors):

• $67.5 — Right at spot, 1.01B total GEX, net GEX −0.71B strongly put-dominant. This is the current gamma pin zone — the near-term magnet. MMs are long puts here and will buy stock on dips, providing a short-term floor at $67.50.
• $70 — 2.67B total GEX, net GEX −0.43B put-dominant. A significant gamma level — puts dominate above AND below current price, meaning MMs will buy dips toward $67.50 but also absorb supply on rallies toward $70. The stock is pinned between these two forces right now.
• $60 — Strong put support further down, 1.95B total GEX, net GEX −1.27B strongly put-dominant. This is the key structural floor below spot — a large put wall that would slow a sell-off toward $60.
• $62.5 — Moderate put support, 0.40B total GEX, net GEX −0.23B put-dominant.
• $55 — The put strike in the trade today. 0.33B total GEX, net GEX −0.25B put-dominant. Meaningful put gamma at this strike — which will expand significantly now that 3,000 new contracts were just added. Post-trade, this level becomes a more prominent gamma anchor.
• $50 — 0.13B total GEX, net GEX −0.08B put-dominant. Smaller but present.

What this means for you: LYB is sitting in a gamma pin zone between $67.50 and $70, with strong put walls acting as cushions on the way down toward $60. A clean break below the $67.50 gamma floor would accelerate toward $65 and then $60. The $60 put wall (1.95B net GEX) is the first major speed bump — a significant sell-off would need to chew through that before heading toward $55. The put buyer today is betting (or hedging) that over 7.5 months, enough catalysts line up to push LYB through the $60 gamma floor and toward $55. Based on today's GEX, that is possible but requires actual fundamental deterioration — gamma alone won't push it there.

---

📐 Implied Move Analysis

The options market is pricing in a wide range of outcomes for LYB across the timeframes that matter for this trade:

The critical data point: By the 2027-01-15 put expiry, the options market's own implied move bracket extends from $37.91 to $96.51 around today's ≈$67.21 price. That means $55 is well within the implied move range — the market is already pricing in the possibility that LYB trades there or lower. The put buyer is not reaching for an extreme — they are buying a move the options market considers plausible.

Looking at the monthly OPEX nearest Q2 earnings (July 17, 2026), the lower boundary is already $56.55 — essentially at the $55 strike. If the Q2 print disappoints (≈July 31), the options market says a slide to $55 is within a single standard deviation of outcomes.

By September (quarterly triple witch), the lower implied range drops to $49.69 — meaning a move all the way through $55 is priced in at ≈1 standard deviation by autumn.

---

🎪 Catalysts

✅ Already Happened (In the Books)

• 🔻 FY2025 Net Loss (−$745M): Revenue fell to $30.2B from $33.4B in 2024 — the full-year loss year is the fundamental backdrop the dividend cut responded to.
• 🔻 ≈50% Dividend Cut (February 20, 2026): LYB cut its quarterly dividend from $1.37 to $0.69, citing an "extended industry downturn" and prioritizing the balance sheet over the payout. This is a management admission that the recovery is not near-term.
• 🔻 BMO Downgrade to Underperform ($36 PT, Dec 2025): BMO Capital cut LYB to Underperform, warning "commodity fundamentals are worse than feared" — no meaningful 2026–2027 earnings recovery expected.
• 🔻 BofA $46 PT (Jan 8, 2026) / Wells Fargo $45 PT (Dec 2025): MarketBeat shows the consensus of cautious analyst targets clustered in the $45–$55 range — all below today's $67 price.
• 🔻 Q1 2026 Earnings (May 1, 2026): Revenue $7.2B, net income $125M, diluted EPS $0.38. A slim profit, and management explicitly credited Middle East war supply disruptions fueling margin expansion — not organic demand recovery. The margin tailwind is exogenous and could evaporate.
• 🔄 European Asset Sale Completed (May 1, 2026): LYB sold four European O&P sites to AEQUITA (now Velogy) — shedding structurally disadvantaged capacity. Bulls call it streamlining; bears call it shrinking into a downturn.
• 🔻 FY2026 EPS Estimates Cut ≈52% in 60 Days: Consensus EPS of ≈$6.31 arrived after analysts slashed estimates repeatedly — a falling-knife dynamic on the numbers even as the stock bounced.
• 🔻 6-Day Losing Streak −8.1% (Late May 2026): LYB has been fading while the S&P 500 rose ≈4.9% over the same period — the relative weakness is a yellow flag.

🚀 Upcoming — Inside the Put's Jan-15-2027 Window

• 📅 Q2 2026 Earnings: ≈July 31, 2026 (≈58 days away) — The most important near-term catalyst. Watch whether the war-driven margin boost persists into Q2, European operating rates (guided ≈80%), I&D operating rates (guided ≈75%), and any commentary on dividend coverage. If margins give back, the stock could reprice quickly.
• 💰 Q2 Dividend Declaration: ≈August 2026 — Any further cut or suspension of the $0.69 quarterly payout would be a major downside catalyst. A hold-flat announcement is stabilizing; a second cut is the bear thesis's single biggest trigger.
• 📅 Q3 2026 Earnings: ≈Late October / Early November 2026 — Second earnings print inside the put's window. By Q3, we will know whether the Middle East margin tailwind persisted or evaporated.
• 💰 Q3 Dividend Declaration: ≈November 2026 — Second dividend declaration inside the put's window. Two chances for the second cut that could gut the yield-buyer base.
• 📉 Chemicals Down-Cycle Continuation Through 2026: ≈10% of global polyolefins capacity (≈21M tonnes) is slated to shut by 2028 — but that is a 2027-2028 story, not a 2026 catalyst. For the duration of this put's life, the oversupply persists.
• ⚖️ Middle East De-Escalation Risk: If the conflict eases and the global cost curve flattens, LYB loses its exogenous margin advantage — a clean path back toward fundamentally-driven pricing in the mid-$50s.

---

🎲 Price Targets & Scenarios Through Jan 2027

Using gamma levels, implied move brackets, and the catalyst calendar:

📉 Bear Case — Put Profits (30% probability by Jan 2027)

Target: $50–$55

How LYB gets there: Q2 or Q3 earnings disappoint as the war-driven margin tailwind fades. Management announces a second dividend cut to protect the balance sheet, triggering forced selling from income funds. FY2026 EPS estimates, already slashed ≈52%, get cut again toward $3–$4 range. The stock re-rates toward the consensus analyst target of $51–$55 — the put buyer's $55 strike — and potentially lower toward BMO's $36 PT.

Put P&L in bear case:

• LYB at $55 on expiry: Put has $0 intrinsic value (at-the-money). Premium already decayed. Breakeven not yet reached — need the stock below $50.
• LYB at $50 on expiry: Intrinsic value $5.00/contract. Net gain = $0 (breakeven). 3,000 contracts = ≈$0 net (recovered full premium).
• LYB at $45 on expiry: Intrinsic value $10.00/contract. Net gain = $5.00/contract × 300 = $500 per contract. 3,000 contracts = ≈$1.5M profit (doubling the premium).
• LYB at $36 (BMO's target): Intrinsic value $19.00/contract. Net gain = $14.00/contract. 3,000 contracts = ≈$4.2M profit (≈2.8× the premium paid).

🎯 Base Case — Put Loses Money (50% probability)

Target: $55–$72 range by Jan 2027

LYB holds up. The margin tailwind persists longer than bears expect. The $0.69 dividend is maintained. The stock drifts sideways-to-slightly-lower, staying above $55. The put expires at $55 (at-the-money, worthless) or decays to a fraction of its $5.00 cost.

Put P&L in base case:

• LYB at $60: Put expires with $0 intrinsic value. Loss: $5.00/contract = full $1.5M premium gone.
• LYB at $58: Same — put is still OTM, expires worthless. Full $1.5M lost.
• Any price above $55 at expiry: Maximum loss = $1,500,000.

📈 Bull Case — Put Worthless (20% probability)

Target: $75+ and holding

Cost-advantaged US feedstock + sustained war disruptions keep margins elevated. The $0.69 dividend is reaffirmed or even raised. ≈21M tonnes of capacity closure begins earlier than expected, tightening the market. The stock rallies back toward $75–$80 (call-gamma resistance zone). Put expires worthless.

Put P&L in bull case: 100% loss of $1.5M premium.

---

💡 Trading Ideas — Four Types of Traders

🎰 YOLO Trader — "Copy the Whale, Scaled Down"

For aggressive traders with $1K-$5K, high-risk tolerance, 7-month horizon

If you share the bear thesis, you can buy a small number of the same put contracts.

• 💸 1 contract × $5.00 × 100 = $500 out-of-pocket
• 📉 Breakeven: LYB at $50 by January 15, 2027
• 🚀 If LYB hits $45: your $500 doubles to ≈$1,000
• 💀 Max loss: $500 (full premium, if LYB stays above $55)

Critical warning: This put is ≈18% out of the money. LYB needs to drop meaningfully AND sustain it through January 2027 for you to profit. The stock has been resilient in 2026 — the ≈60% YTD bounce shows real buying interest. You need two earnings disappointments and possibly a second dividend cut to get there. Size this as a speculative position, not a core holding.

---

📊 Swing Trader — "Wait for the Crack, Then Play Closer Expiry"

For swing traders with $5K-$20K, 1-3 month view

Rather than copying the 7-month LEAP put, consider waiting for Q2 earnings (≈July 31, 2026) to confirm or deny the bear thesis. If Q2 margins give back and the stock breaks below the $67.50 gamma floor, a shorter-dated Aug/Sep put spread offers a better risk-reward than the Jan-2027 put at current elevated vol.

Structure (illustrative — verify live prices):

• 📉 Buy LYB $65 Put, 2026-09-18 expiration
• 📈 Sell LYB $57.5 Put, 2026-09-18 expiration (reduces cost)
• 💰 Net debit: ≈$3–4 per spread (estimate; verify live)
• 🎯 Max profit: ≈$3.50–4.50 if LYB is below $57.5 at September expiry
• ⚠️ Max loss: the net debit paid

Why this works: You get cleaner risk definition and avoid paying full premium on a 7-month hold. The September expiry captures both Q2 earnings (July 31) and covers through early Q3 — the two biggest near-term catalysts. The $65 put is closer to the money (less OTM than $55), giving better probability of profit if the stock fades.

---

🛡️ Premium Collector — "Sell Puts Below the Gamma Floor"

For income-focused traders with $20K+, neutral-to-bullish LYB view

If you believe LYB holds above $60 (the major put-gamma support floor), selling a cash-secured $60 put for August or September collects premium while the stock stays elevated.

Structure (illustrative):

• 💰 Sell 1 LYB $60 Put, 2026-08-21 expiration
• 📥 Premium collected: ≈$4–5 per contract (estimate)
• 🎯 Keep premium if LYB stays above $60 at expiry
• ⚠️ Assignment risk: if LYB falls below $60, you acquire the stock at $60 less the premium — effective cost ≈$55–$56

Why this works: The $60 level has strong put-gamma support (1.95B total GEX, net −1.27B) — market makers will defend it. The $0.69 quarterly dividend (≈4.1% annualized) also provides a cushion. If assigned, you collect dividends at a ≈4.2% annualized yield at $60 cost basis.

Risk: If LYB breaks through $60 (possible on a dividend cut surprise), losses can mount quickly.

---

👶 Entry-Level Investor — "Understand the Trade Before Copying It"

For options newcomers

Here's what you need to understand before touching this trade:

The risk/reward math is straightforward but unforgiving:

• You pay $500 per contract ($5.00 × 100 shares) upfront — that money is at risk immediately
• LYB needs to fall ≈25% from today's price ($67.30 → $50) just for you to break even — that's a lot of stock decline to need
• The stock could fall 10% to $60 and your put still loses money at expiration

A safer way to express a bearish or cautious view:

• 📅 Watch Q2 earnings on ≈July 31 first — if the margin story starts to crack, the evidence becomes clearer
• 🛡️ Consider buying just 1 put as a "learning trade" with $500 at risk, not 10+ contracts
• 📖 The put is most valuable as portfolio insurance — if you actually own LYB stock and are worried about a dividend cut, buying a put below your cost basis makes logical sense as protection

Bottom line for beginners: this is a sophisticated institutional trade that requires a fairly specific chain of events (margin give-back + dividend risk + continued oversupply) to be profitable. Do your homework on the chemicals cycle before following along.

---

⚠️ Risks & Honest Limits

What the tape CANNOT tell us:

• 🤔 Outright bearish vs. hedge — we cannot tell. The most important uncertainty: this could be a $1.5M bearish directional bet on LYB falling, OR it could be a hedge on a large long LYB stock position (perhaps a yield-focused fund protecting its dividend-income investment). Both produce the exact same options print. The trade looks identical whether the buyer is short LYB in spirit or long LYB in fact. We honestly do not know which — present both readings when discussing with others.
• 🏦 Broker/MMID/identity: The tape tells us the print happened; it does not tell us which institution placed it, what their underlying stock position is, or their internal reasoning.
• 🔄 Counterparty motivation: In a block cross, there is a seller on the other side who was willing to write these puts at $5.00 — they believe LYB stays above $55 through January 2027. The seller is also smart; neither side of a block cross is obviously "right."
• ⏳ Next-day OI is still pending: The MED-confidence BTO classification will be confirmed (or challenged) by tomorrow's OPRA OI snapshot at ≈06:30 ET, June 4. The Vol/OI ratio of 9.8 makes this a high-probability open, but not 100% provable until OI resolves.

What could defeat the puts (the honest bull case):

• 💪 LYB's US gas feedstock cost advantage is structural and long-lasting — margins could stay elevated well above $55 even without the war tailwind
• 💵 The ≈$3.4B cash cushion gives management room to maintain the $0.69 dividend through a down year without another cut
• 📉 The ≈4.1% dividend yield at $67 is already "reset" — the big yield risk event (the Feb 2026 cut) has already happened, reducing the surprise risk going forward
• 🔄 ≈21M tonnes of global capacity closure by 2028 disproportionately benefits LYB's modern, low-cost plants — the market may start pricing this recovery earlier than the put implies
• 📊 The ≈60% YTD 2026 bounce demonstrates real institutional buyer interest, creating a technical bid that could keep the floor above $55 even in a challenging fundamental environment

---

🎯 The Bottom Line

Real talk: Someone paid $1.5M to own 7.5 months of downside protection at $55 on a chemicals company that just bounced ≈60% off multi-year lows on a margin tailwind that management itself says is driven by war-disrupted supply chains. The $55 strike is not a random number — it is exactly where BMO ($36), Wells Fargo ($45), and BofA ($46) cluster, and the average analyst target from stockanalysis.com is in the low-to-mid $50s. This trade is literally buying the Street's consensus base case as a floor.

If you own LYB:

• 🎯 This put flow is a signal to take the dividend sustainability question seriously. Mark Q2 earnings (≈July 31) and the ≈August dividend declaration as the two make-or-break events for the stock's near-term direction
• 🛡️ The $60 gamma floor (1.95B total GEX, strongly put-dominant) is the technical line in the sand — a sustained break below $60 opens the door to the $55 level the put buyer is targeting

If you're watching from the sidelines:

• 📅 July 31, 2026 — Q2 earnings is the first major read on whether the war-margin tailwind is fading
• 💰 ≈August 2026 — dividend declaration. Maintained = stabilizing. Cut = catalyst for the put
• 📅 Late Oct / Early Nov 2026 — Q3 earnings: second opportunity in the put's window
• 💰 ≈November 2026 — second dividend declaration. By then, the put buyer will know if the thesis is playing out

Mark your calendar:

• 📅 June 4, 2026 pre-market (≈06:30 ET) — Check LYB $55 Jan-2027 put OI; BTO confirmed if OI rises from ≈307 toward ≈3,000–3,307
• 📅 ≈July 31, 2026 — Q2 2026 earnings (war-margin sustainability test)
• 📅 ≈August 2026 — Q2 dividend declaration (second cut risk)
• 📅 ≈Late Oct / Early Nov 2026 — Q3 2026 earnings
• 📅 ≈November 2026 — Q3 dividend declaration
• 📅 January 15, 2027 — Put expiration date

Final verdict: The bear/hedge thesis is well-supported by fundamentals — a ≈50% dividend cut already in the books, a FY2025 net loss, EPS estimates slashed ≈52% in 60 days, and analyst targets clustered at or below the $55 strike. But the counterargument is real: LYB's feedstock advantage is structural, the dividend is already reset lower, and ≈$3.4B of cash provides a buffer. The honest read is that this trade is most likely an institutional hedge against a LYB long or dividend position — or a well-structured bearish bet from a desk that has done the chemicals-cycle math. Either way, $1.5M in premium has a $1.5M maximum loss if LYB stays above $55 through January 2027. Come back June 4 pre-market before drawing final conclusions.

---

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. Long puts can expire entirely worthless — a $5.00/contract premium is 100% at risk if LYB trades above $55 on January 15, 2027. This analysis is for educational purposes only and not financial advice. The order-type classification (BTO Long Put) is based on a Vol/OI ratio of ≈9.8 and carries MED confidence — it will be confirmed or revised by the June 4 OPRA OI snapshot. The tape cannot distinguish between an outright bearish directional bet and a hedge on an existing long stock position. Past unusual options activity does not guarantee profitable trading outcomes. Always do your own research and consult a licensed financial advisor before trading.

---

Last updated: 2026-06-03

About LyondellBasell Industries: LyondellBasell is one of the world's largest plastics, chemicals, and refining companies, specializing in olefins & polyolefins, intermediates & derivatives, advanced polymer solutions, and technology licensing. Market cap ≈$21.5–22 billion. Sector: Materials / Commodity Chemicals. The company is navigating one of the deepest chemicals down-cycles in decades following a FY2025 net loss and a ≈50% dividend cut in February 2026.